Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recom...(iologists are physicians who specialize ...),Health

Date:9/4/2008

iologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, usually in an artery, to treat at the source of the disease internally. As the inventors of angioplasty and the catheter-delivered stent, which were first used in the legs to treat peripheral arterial disease, interventional radiologists pioneered minimally invasive modern medicine.

Today, interventional radiology treatments are first-line care for many conditions that once required surgery. Interventional radiology treatments generally offer less risk, less pain and less recovery time compared to open surgery. In 2008, the Society of Interventional Radiology (SIR) celebrates 35 years of quality patient care innovation. Visit http://www.SIRweb.org.

'/>"/>

SOURCE Society of Interventional Radiology Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3
Related medicine technology :

1. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
2. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
3. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
5. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
6. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
7. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
8. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
9. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
10. Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
11. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting